Healthcare company Dassault Systèmes (Euronext Paris: FR0014003TT8) (DSY.PA) announced on Wednesday that it has invested in Click Therapeutics, a provider of prescription digital therapeutics (PDTs). This move strengthens the ongoing collaboration between Dassault's MEDIDATA brand and Click Therapeutics, aimed at enhancing patient engagement from clinical trials through commercialisation.

The partnership will leverage Dassault's global expertise and MEDIDATA's integrated technology solutions to advance the development of PDTs and software-enhanced (SE) drugs. These innovations, combining software with traditional drug therapies, are designed to provide additional clinical benefits for patients. By integrating digital therapeutics into real-world care, the collaboration will improve coordination and outcomes among patients, healthcare providers and life sciences manufacturers.

Digital therapeutics are evidence-based software interventions used to prevent or treat medical conditions. PDTs, a subset of digital therapeutics, are regulated as medical devices and require a prescription. SE drugs combine a medication with a digital therapeutic to enhance treatment efficacy.

This investment aligns with Dassault Systèmes' broader commitment to transforming the healthcare experience, utilizing AI-powered solutions to drive innovation in the life sciences and healthcare sectors.